Navigation Links
Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
Date:8/7/2008

KOBE, Japan, Aug. 8 /PRNewswire/ -- Carna Biosciences, Inc. ("Carna") is pleased to announce the signing of a collaborative agreement with Caliper Life Sciences, Inc. USA ("Caliper") on August 6 (US Eastern Daylight Time). Carna will supply a set of discrete protein kinases aiding the expansion of Caliper's kinase profiling and assay development services, and ProfilerPro Kinase Selectivity Assay Kits. Caliper's products and services are widely used and highly regarded by leading pharmaceutical and biotech companies. The selection of Carna as a Preferred Provider enhances the visibility and use of Carna's products in the area of kinase inhibitor drug discovery -- a major focus of targeted therapy in the areas of cancer, neurological, and autoimmune diseases.

"I am proud of the expression and purification technologies that Carna has developed in order to produce nearly 300 human kinases to date, and even more pleased that Caliper has selected Carna Biosciences as a principle supplier for Caliper's ProfilerPro Kits," said Kohichiro Yoshino, President and CEO of Carna Biosciences. "Caliper is an established and reliable partner to the pharmaceutical and biotech industry.

Working with Caliper provides Carna with access to a wealth of new opportunities to expand sales of protein kinases throughout the worldwide market. This synergistic impact of combining Caliper's advanced instrumentation with the wide selection and premier quality reagents provided by Carna will greatly benefit both companies and their clients. We anticipate that this expanded relationship with Caliper will further position us to explore R&D Partnerships with global biopharmaceutical companies.

About Carna Biosciences, Inc.

Carna Biosciences, Inc. (http://www.carnabio.com), founded in April 2003, is a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs, as well as providing drug discovery services to pharmaceutical companies, using proprietary technologies in gene cloning, active kinase protein expression, protein purification and homogeneous assay development.

The company provides products and services including protein kinases, profiling and screening services, assay development services and crystallography products and services.

About Caliper Life Sciences, Inc.

Caliper Life Sciences, Inc. (http://www.caliperls.com) is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions.

Contact:

Tomohisa Yamazaki,

Manager

Corporate Planning

Carna Biosciences, Inc.

Phone: +81-78-302-7039

Fax: +81-78-302-6665

E-mail: ir-team@carnabio.com

URL: http://www.carnabio.com


'/>"/>
SOURCE Carna Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics
3. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
4. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
5. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
6. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
7. Neurocrine Biosciences Reports Second Quarter 2008 Results
8. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
9. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
11. SuperArray Bioscience Changes Name to SABiosciences and Moves Into New Larger Facility on Verge of Tenth Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):